Jugular venous pressure

V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session & Expo

Retrieved on: 
Thursday, March 28, 2024
Patient, Hospital, Heart failure, American College, Death, ACC, Heart, Jugular venous pressure, Pharmaceutical industry

CAESAREA, Israel, March 28, 2024 /PRNewswire/ -- V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology's (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta.

Key Points: 
  • CAESAREA, Israel, March 28, 2024 /PRNewswire/ -- V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology's (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta.
  • RELIEVE-HF is a randomized, double-blind, placebo-procedure-controlled, multicenter, multinational, pivotal trial of the
    V-Wave® Ventura® Interatrial Shunt in symptomatic patients with reduced (HFrEF) or preserved (HFpEF) left ventricular ejection fraction at high risk of heart failure (HF)-related events.
  • "We're pleased to present the RELIEVE-HF data at this year's ACC meeting, as we continue to advance this important technology with the goal of bringing a much-needed treatment option to patients with advanced heart failure, a leading cause of death and hospitalization in the U.S. and worldwide," said Neal Eigler, M.D., CEO of V-Wave.

Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

Retrieved on: 
Wednesday, June 7, 2023
Steatosis, Abstract, Insulin resistance, EASL, Histology, European Association for the Study of the Liver, NASH, CAP, PPAR, Diabetes, Jugular venous pressure, Liver disease, Biomarker, Inflammation, Fibrosis, Euronext Paris, GW501516, Metabolism, Patient, Splanchnic, Fatty liver disease, ALT, NAFLD, European Association for the Study of Diabetes, Adiponectin, Isotope, Medical imaging, Pharmaceutical industry, Silviculture, Liver, Rosiglitazone, Fenofibrate

the reduction of the increased portal pressure and improvement of steatosis in a rat model of early NAFLD following a 4-week lanifibranor treatment.

Key Points: 
  • the reduction of the increased portal pressure and improvement of steatosis in a rat model of early NAFLD following a 4-week lanifibranor treatment.
  • the greater reduction of the increased portal pressure associated with early NAFLD following lanifibranor treatment compared to the PPAR agonists α, δ  or γ individually.
  • The hepatic  steatosis was measured by histological grading and by imaging using Controlled Attenuation Parameter (“CAPTM”) Fibroscan®.
  • The fourth abstract evaluates the effect of lanifibranor on portal pressure, endothelial dysfunction and liver histology in a rat model of early NAFLD.

V-Wave Announces Appointment of Bill Hughes as Chief Financial Officer

Retrieved on: 
Wednesday, December 2, 2020
Medical specialties, Clinical medicine, Anatomy, Hypertension, Pulmonary hypertension, Shunt, Heart, Cerebral shunt, Jugular venous pressure, Primary interatrial foramen

CAESAREA, Israel and AGOURA HILLS, Calif., Dec. 2, 2020 /PRNewswire/ --V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced the appointment of Bill Hughes as its Chief Financial Officer (CFO) today.

Key Points: 
  • CAESAREA, Israel and AGOURA HILLS, Calif., Dec. 2, 2020 /PRNewswire/ --V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced the appointment of Bill Hughes as its Chief Financial Officer (CFO) today.
  • "We are thrilled to add someone with Bill's talent and experience to the V-Wave management team," said Dr. Neal Eigler, V-Wave's CEO.
  • "Bill will be an essential part of our effort to bring V-Wave's ground-breaking technology to heart failure patients around the world."
  • CAUTION: The V-Wave Ventura Interatrial Shunt System is not available for sale in the United States or other countries.